Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
Danielle M Brander, Anne W BeavenDuke University Medical Center, Durham, NC, USAAbstract: Follicular lymphoma is predominantly managed as a chronic disease, with intermittent chemo/immunotherapy reserved for symptomatic progression. It is considered incurable with conventional treatments, and curren...
Main Authors: | Brander DM, Beaven AW |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-03-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/update-on-treatment-of-follicular-non-hodgkinrsquos-lymphoma-focus-on--a9555 |
Similar Items
-
Bendamustine in the treatment of non-Hodgkin’s lymphomas
by: Fredrick Hagemeister, et al.
Published: (2009-12-01) -
Rituximab in the treatment of non-Hodgkin’s lymphoma
by: Beate Hauptrock, et al.
Published: (2008-09-01) -
Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma
by: Michael J Burdick, et al.
Published: (2009-08-01) -
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
by: Rudolf Weide
Published: (2008-09-01) -
Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
by: McKinney MS, et al.
Published: (2014-08-01)